Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Richard Stone and Martha Wadleigh.
Richard Stone
Connection Strength
2.903
Martha Wadleigh
  1. The role of myeloid growth factors in acute leukemia. J Natl Compr Canc Netw. 2009 Jan; 7(1):84-91.
    View in: PubMed
    Score: 0.397
  2. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30.
    View in: PubMed
    Score: 0.295
  3. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
    View in: PubMed
    Score: 0.166
  4. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34.
    View in: PubMed
    Score: 0.146
  5. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
    View in: PubMed
    Score: 0.139
  6. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
    View in: PubMed
    Score: 0.067
  7. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 Mar 15; 1-8.
    View in: PubMed
    Score: 0.062
  8. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 Mar; 107:14-19.
    View in: PubMed
    Score: 0.061
  9. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021 12 14; 5(23):5086-5097.
    View in: PubMed
    Score: 0.061
  10. Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
    View in: PubMed
    Score: 0.058
  11. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9.
    View in: PubMed
    Score: 0.058
  12. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
    View in: PubMed
    Score: 0.057
  13. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.052
  14. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.050
  15. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.048
  16. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.047
  17. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
    View in: PubMed
    Score: 0.047
  18. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.046
  19. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566.
    View in: PubMed
    Score: 0.044
  20. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.042
  21. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.042
  22. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
    View in: PubMed
    Score: 0.041
  23. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
    View in: PubMed
    Score: 0.041
  24. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.041
  25. Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99.
    View in: PubMed
    Score: 0.040
  26. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
    View in: PubMed
    Score: 0.040
  27. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
    View in: PubMed
    Score: 0.039
  28. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98.
    View in: PubMed
    Score: 0.039
  29. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.039
  30. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View in: PubMed
    Score: 0.038
  31. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10.
    View in: PubMed
    Score: 0.038
  32. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
    View in: PubMed
    Score: 0.036
  33. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther. 2014 May; 13(5):1194-205.
    View in: PubMed
    Score: 0.035
  34. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
    View in: PubMed
    Score: 0.035
  35. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
    View in: PubMed
    Score: 0.034
  36. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003.
    View in: PubMed
    Score: 0.034
  37. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013 Jul; 37(7):747-51.
    View in: PubMed
    Score: 0.034
  38. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
    View in: PubMed
    Score: 0.032
  39. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
    View in: PubMed
    Score: 0.032
  40. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
    View in: PubMed
    Score: 0.030
  41. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5.
    View in: PubMed
    Score: 0.029
  42. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7.
    View in: PubMed
    Score: 0.028
  43. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
    View in: PubMed
    Score: 0.027
  44. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
    View in: PubMed
    Score: 0.026
  45. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7.
    View in: PubMed
    Score: 0.025
  46. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9.
    View in: PubMed
    Score: 0.025
  47. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54.
    View in: PubMed
    Score: 0.023
  48. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Jan; 19(1):27-30.
    View in: PubMed
    Score: 0.019
  49. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.